Moon Surgical
Moon Surgical (previously MastOR SAS) is a Paris-based, early-stage medical device company, developing a surgical robot for laparoscopy assistance. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund. The core technology is derived from joint research between the ISIR robotics lab at Sorbonne University and Professor Brice Gayet, a world-renowned surgeon and pioneer in minimally-invasive surgery.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.moonsurgical.com
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Related News
Moon Surgical receives second FDA clearance, covering its commercial Maestro™ surgical robotics system
Moon Surgical expands to gynecological surgery
Moon Surgical's Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated
Arnault Tzanck Institute in Nice, France, completes inaugural robotics surgeries with Moon Surgical's Maestro commercial system
Moon Surgical announces CE Mark for its commercial Maestro System
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.